3 employees
Serenity is developing antibody mimetics for targeted protein degradation.
2017
Serenity Bioworks raised undisclosed on February 27, 2019
Investors: IndieBio and SOSV - The Accelerator VC
Serenity Bioworks raised undisclosed on June 22, 2018